OncoMed (OMED) Target Lifted to $46 at Jefferies after Celgene Deal
Tweet Send to a Friend
Jefferies analyst Thomas Wei reiterated a Buy rating and boosted its price target on OncoMed Pharmaceuticals (NASDAQ: OMED) from $27 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
